Corporate Infomation Perseus Proteomics Inc. [as of August 1, 2011] Company name Perseus Proteomics Inc. Corporate headquarters 4-7-6, Komaba Meguro-ku, Tokyo 153-0041, JAPAN Telephone : +81-3-5738-1705 FAX : +81-3-3481-5760 URL : http://ppmx.com/en/ Established February 1, 2001 Capital 1,693,250,000 Yen Number of employees 28 Board of Directors President & CEO Akiyuki Furuya CTO Yukio Sudou Kazuo Nakamura (CMIC Co., Ltd., Chaiman & CEO) Yuzo Toda (FUJIFILM Holdings, Board of Director) Takao Hamakubo, Professor, M.D., Ph.D. (The University of Tokyo) Statutory Auditors Hiroshi Matsushita, Ph.D. Haruyuki Saito (FUJIFILM Corporation) Masaaki Otani (FUJIFILM Corporation) Scientific advisory board Research Institute Name Research Area The University of Tokyo Tatsuhiko Kodama, Professor, M.D., Ph.D. Vascular System Biology The University of Tokyo Hiroyuki Abratani, Professor, M.D., Ph.D. Cancer genomics The University of Tokyo Toshiya Tanaka, Asssociate Professor, Ph.D. Molecular endocrinology and metabolism Corporate History February, 2001 Founded as a biotech venture company using technology developed at the Laboratory for System Biology and Medicine (LSBM), a division of the Research Center for Advanced Science and Technology (RCAST) at the University of Tokyo. October, 2002 Established a research and development laboratory at Komaba, Meguro-ku, Tokyo. April, 2003 Participated in government sponsored national project entitled "Bionanochip for the Analysis of Protein Interactions" (project leader: Dr. Tatsuhiko Kodama), administered by the New Energy and Industrial Technology Development Organization (NEDO). May, 2004 Establishment of a joint partnership with CMIC Co., Ltd (Tokyo, Japan) for the development and production of diagnostic kits targeting PTX3, a promising biomarker for arteriosclerosis. August, 2004 Signed an agreement with R&D Systems Inc. (Minnesota, USA) for the sale and distribution of Perseus Proteomics nuclear receptor monoclonal antibodies January, 2006 Raised $9.5m (1.1 billion yen) from Fuji Photo Film Co., Ltd., IRI Finance and Technology, Inc., a subsidiary of Internet Research Institute, Inc., and venture capital. April, 2008 PPMX presented the research progress of AMIGO2 at AACR Meeting. September, 2008 PPMX's anti-GPC3 antibody entered into clinical trial in the USA. January, 2009 PPMX received one billion yen from FUJIFILM in a third-party allocation of shares, and became a subsidiary company of FUJIFILM.